List of SBIR/STTR awards granted to Scribe Biosciences, Inc.
Scribe Biosciences, Inc.Name | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase I contract was awarded to Scribe Biosciences, Inc. in September, 2022 for $349,997.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43CA277934-01 | Phase I | 349,997 | September 7, 2022 | |||||||
A STTR Phase I contract was awarded to Scribe Biosciences, Inc. in February, 2020 for $225,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R41GM136037-01 | Phase I | 225,000 | February 7, 2020 | |||||||
A SBIR Phase I contract was awarded to Scribe Biosciences, Inc. in September, 2019 for $350,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43HG010592-01A1 | Phase I | 350,000 | September 1, 2019 | |||||||
A SBIR Phase I contract was awarded to Scribe Biosciences, Inc. in April, 2018 for $280,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43HG010128-01 | Phase I | 280,000 | April 20, 2018 | |||||||
A SBIR Phase I contract was awarded to Scribe Biosciences, Inc. in March, 2018 for $220,661.0 USD from the U.S. Department of Defense and DARPA. | SBIR | 140D6318C0010 | Phase I | 220,661 | March 7, 2018 | |||||||
A SBIR Phase II contract was awarded to Scribe Biosciences, Inc. in September, 2017 for $1,492,018.0 USD from the U.S. Department of Defense. | SBIR | D17PC00405 | Phase II | 1,492,018 | September 13, 2017 | |||||||
A SBIR Phase I contract was awarded to Scribe Biosciences, Inc. in February, 2019 for $225,000.0 USD from the National Science Foundation. | SBIR | 1843954 | Phase I | 225,000 | February 1, 2019 | |||||||
A SBIR Phase I contract was awarded to Scribe Biosciences, Inc. in August, 2023 for $300,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI177129-01 | Phase I | 300,000 | August 1, 2023 |
